podophyllotoxin has been researched along with cytarabine in 195 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 46 (23.59) | 18.7374 |
| 1990's | 35 (17.95) | 18.2507 |
| 2000's | 58 (29.74) | 29.6817 |
| 2010's | 51 (26.15) | 24.3611 |
| 2020's | 5 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Hansch, C; Khwaja, TA; Selassie, CD | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Comelli, A; Massimo, L | 1 |
| Grieder, A; Maurer, R; Stähelin, H | 1 |
| Bender, RA; Chabner, BA; Cohen, M; Doroshow, JH; Hande, KR; Locker, GY; Murinson, DS; Myers, CE; Zwelling, LA | 1 |
| Dubovsky, D; Jacobs, P; Kernoff, L | 1 |
| Dombernowsky, P; Nissen, NI | 1 |
| Alberto, P; Cavalli, F; Sauter, C; Senn, HJ | 1 |
| Comay, S; Dubovsky, D; Hougaard, M; Jacobs, P | 1 |
| Dubovsky, D; Jacobs, P | 1 |
| Avery, T; Rivera, G; Roberts, DW | 1 |
| Adam, M; Baruchel, A; Brice, P; Dombret, H; Gisselbrecht, C; Lepage, E; Marolleau, JP; Miclea, JM; Sitthy, X | 1 |
| Hines, LH; White, JC; Wright, SE | 1 |
| Ehrsson, H; Eksborg, S | 1 |
| Iwabuchi, M; Takahashi, K | 1 |
| Carde, P; Ganem, G; Gouyette, A | 1 |
| Douay, L; Fouillard, L; Gorin, NC; Isnard, F; Laporte, JP; Najman, A | 1 |
| Newlands, ES | 1 |
| Ishida, R; Nishimoto, T; Nishizawa, M; Takahashi, T | 1 |
| Becton, DL; Chaffee, S; Falletta, JM; Friedman, HS; Kinney, TR; Kurtzberg, J | 1 |
| Bezanilla Regato, JL; Moya Calderón, E; Navajas Gutiérrez, A; Piñán, MA | 1 |
| Rivera, GK | 1 |
| Grem, JL; Hoth, DF; King, SA; Leyland-Jones, B; Ungerleider, RS; Wittes, RE | 1 |
| Huijgens, PC; Ossenkoppele, GJ; Reijneke, RM; Thomas, LL; van der Lelie, J; Wijngaarden, MJ | 1 |
| Akisawa, M; Ikeda, K; Kamano, H; Kubota, Y; Nagai, M; Ohnishi, H; Sasaki, K; Shimada, Y; Tanaka, T; Taoka, T | 1 |
| Forman, SJ; Levitt, LJ; Linker, CA; O'Donnell, M; Ries, CA | 1 |
| Büchner, T; Ganser, A; Heil, G; Heimpel, H; Hoelzer, D; Koch, P; Kurrle, E; Lipp, T; Löffler, H; Thiel, E | 1 |
| Anderson, CC; Cawley, JC; Goldstone, AH; Harper, PG; Jelliffe, AM; Jones, M; Linch, DC; Machin, SJ; McLennan, KA; Souhami, RL | 1 |
| Chan, HY; Lewis, JP; Meyers, FJ | 1 |
| Abromowitch, M; Dahl, GV; Kalwinsky, DK; Look, AT; Mirro, J; Murphy, SB; Ochs, J; Pui, CH; Rivera, G | 1 |
| Gomis, F; Lorenzo, I; Martín-Aragonés, G; Martínez, JA; Marty, ML; Rafecas, FJ; Sanz, G; Sanz, MA | 1 |
| Jacobs, P | 1 |
| Arakawa, S; Esumi, N; Imashuku, S; Todo, S | 1 |
| Hines, LH; Rathmell, JP; White, JC | 1 |
| Burchenal, JH; Carter, SK | 1 |
| Baehner, R; Chard, R; Hammond, D; Higgins, G; Movassaghi, N; Pyesmany, A; Sather, H | 1 |
| Bertino, JR; Cadman, E; Vera, R; Waldron, JA | 1 |
| Arakawa, S; Esumi, N; Imashuku, S | 1 |
| Catovsky, D; Galton, DA; Goldman, JM; Islam, A | 1 |
| Carreras, E; Grañena, A; Marín, P; Olivé, MT; Rozman, C; Sierra, J | 1 |
| Rafecas, FJ; Sanz, MA | 1 |
| Dubovsky, DW; Jacobs, P; Wood, L | 1 |
| Kardos, G; Révész, T; Schuler, D; Vargha, M | 1 |
| Aur, RJ; Avery, TL; Bowman, WP; Dahl, GV; Rivera, G; Wood, A | 1 |
| Simone, JV | 1 |
| Dubovsky, DW; Jacobs, P; Kernoff, LM | 1 |
| Aur, RJ; Avery, TL; Bowman, WP; Dahl, GV; Murphy, SB; Rivera, G; Simone, JV | 1 |
| Aur, RJ; Avery, TL; Dahl, GV; Pratt, CB; Rivera, G; Wood, A | 1 |
| Hilliard, S; Peck, C; Roberts, D | 1 |
| Dercksen, MW; Dirkson, MK; Gerritsen, WR; Pinedo, HM; Rodenhuis, S; Schaasberg, WP; Slaper-Cortenbach, IC; van der Schoot, CE; von dem Borne, AE | 1 |
| Bastion, Y; Brice, P; Coiffier, B; Espinouse, D; Gisselbrecht, C; Haioun, C; Marolleau, JP; Reyes, F; Salles, G; Sonet, A | 1 |
| Allen, PD; Castenskiold, EC; Coldwell, RD; Collins, PW; Goldstone, AH; Kelsey, SM; Makin, HL; Newland, AC; Side, LE | 1 |
| Crowther, D; Ghielmini, M; Morgenstern, GR; Pettengell, R; Radford, JA; Scheid, C; Stern, PL | 1 |
| Hino, K; Nakamaki, T | 1 |
| Chatterjee, R; Goldstone, AH; Katz, M; McGarrigle, HH; Mills, W | 1 |
| Phillips, GL; Reece, DE | 1 |
| Brandwein, JM; Colwill, R; Couture, F; Crump, M; Danish, R; Keating, A; Scott, JG; Stewart, AK; Sutcliffe, SB; Sutton, DM | 1 |
| Brice, P; Castaigne, S; Gisselbrecht, C; Marolleau, JP; Pautier, P | 1 |
| Barge, A; Boogaerts, MA; Demuynck, HM; Dreger, P; Ferrant, A; Goldstone, AH; Linch, DC; Link, H; Schmitz, N; Zander, A | 1 |
| Billingham, LJ; Knechtli, CJ; Long, SG; Lumley, MA; McDonald, DF; Milligan, DW | 1 |
| Ager, S; Baglin, TP; Barker, P; Bass, G; Bloxham, DM; Boraks, PA; Hood, IM; Jestice, HK; Johnson, D; Mahendra, P; Marcus, RE; Scott, MA | 1 |
| Haynes, AP; Iqbal, A; McQuaker, IG; Russell, NH | 1 |
| de Kreuk, AM; Dräger, AM; Huijgens, PC; Jonkhoff, AR; Legdeur, MC; Oberink, JW; Ossenkoppele, GJ; Schuurhuis, GJ; Westra, G; Zweegman, S | 1 |
| Anderson, L; Linch, DC; Vaughan Hudson, B; Vaughan Hudson, G | 1 |
| Batan, ZE; Milanovich, NF; Skriagin, AE; Snegir', VM; Uss, AL; Zmachinskiĭ, VA | 1 |
| Caballero, MD; Corral, M; del Cañizo, MC; García-Sanz, R; Gonzalez, M; Heras, I; Jean-Paul, E; León, A; Moraleda, JM; Rifon, J; Rocha, E; Rubio, V; San Miguel, JF; Vázquez, L; Vidriales, B | 1 |
| Geisler, C; Myhre, J; Pedersen, M; Pedersen-Bjergaard, J | 1 |
| Caballero, D; del Cañizo, C; García-Sanz, R; González, M; Heras, I; Jean-Paul, E; León, A; Pérez-Simón, JA; Rifon, J; Rocha, E; Rubio, V; San Miguel, JF; Vicente, V; Vidriales, B | 1 |
| Andreeff, M; Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, CA; Kornblau, SM; O'Brien, S | 1 |
| Chen, PM; Chiou, TJ; Fang, FS; Hsieh, RK; Liu, JH; Tung, SL; Tzeng, CH; Wang, WS; Yen, CC | 1 |
| Devereux, S; Goldstone, AH; Leverett, D; Linch, DC; Peniket, AJ; Perry, AR; Sullivan, AM; Watts, MJ; Williams, CD | 1 |
| Cooper, DL; D'Andrea, E; Hu, GL; Jillella, AP; Nadkarni, R; Salloum, E; Seropian, S; Zelterman, D | 1 |
| Azaceta, G; Palomera, L; Soria, J; Varo, MJ | 1 |
| Amigo, ML; del Cañizo, MC; Gonzalez, MB; Gutiérrez, N; Hernández, JM; Mateos, MV; San Miguel, JF | 1 |
| Barta, A; Batai, A; Kelemen, E; Lengyel, L; Paloczi, K; Petranyi, GG; Sipos, A; Torbagyi, E | 1 |
| Bamborschke, S; Diehl, V; Feiden, W; Lehrke, R; Re, D; Schröder, R; Tesch, H | 1 |
| Burtness, B; Cooper, DL; Hu, GL; Jillella, AP; Nadkarni, R; Salloum, E; Seropian, S; Zelterman, D | 1 |
| Anderlini, P; Andersson, B; Braunschweig, I; Champlin, R; Claxton, D; Cleary, K; Donato, M; Folloder, J; Gajewski, J; Giralt, S; Hagemeister, F; Khouri, I; Körbling, M; Mehra, R; Molldrem, J; Przepiorka, D; Samuels, B; Ueno, NT; van Besien, K | 1 |
| Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D | 1 |
| Aguado, MJ; Canales, MA; de Bustos, JG; Fernández-Jiménez, MC; Hernández-Navarro, F; Ojeda, E | 1 |
| Buijt, I; Huijgens, PC; Ossenkoppele, GJ; Uyl-de Groot, CA | 1 |
| Amylon, M; Barredo, JC; Borowitz, M; Camitta, BM; Kurtzberg, J; Laver, JH; Link, MP; Murphy, SB; Pullen, J; Ravindranath, Y; Schwenn, M; Shuster, J | 1 |
| Byrne, JL; Carter, GI; Cull, GM; Hale, G; Haynes, AP; Miflin, G; Rebello, P; Russell, NH; Waldmann, H | 1 |
| Bruty, SJ; Duncombe, AS; George, P; Sweetenham, JW; Wyre, RM | 1 |
| Brion, A; Casassus, P; Colombat, P; Deconinck, E; Delwail, V; Foussard, C; Gaillard, F; Lamy, T; Lemevel, A; Milpied, N | 1 |
| Björkholm, M; Gruber, A; Hansson, M; Steingrimsdottir, H; Svensson, A | 1 |
| Clark, RE; Durham, BH; Flory, AJ; Fraser, WD; Ion, EM; Woodcock, BE | 1 |
| Jantunen, E; Mahlamäki, E; Nousiainen, T | 1 |
| Berger, M; Boiret, N; Deméocq, F; Halle, P; Kanold, J; Malpuech, G; Paillard, C; Rapatel, C; Yakouben, K | 1 |
| Avigdor, A; Ben-Bassat, I; Grotto, I; Hardan, I; Raanani, P; Shpilberg, O | 1 |
| Caballero, MD; Canales, MA; Fernández-Jiménez, MC; García de Bustos, J; Hernández-Navarro, F; Martín, A; Pérez-Simón, JA; San Miguel, JF; Vázquez, L | 1 |
| Kashyap, A; Snowden, J | 1 |
| Inwards, DJ; Lacy, MQ; Markovic, SN; Porrata, LF | 1 |
| Becherer, A; Dudczak, R; Greinix, HT; Jaeger, U; Kalhs, P; Karanikas, G; Kletter, K; Mitterbauer, M; Pötzi, C; Raderer, M | 1 |
| Estlin, EJ; Lowis, SP; Yule, SM | 1 |
| Buerger, T; Gebauer, T; Halloul, Z; Meyer, F | 1 |
| Carella, A; de Elvira, CR; Goldstone, AH; Mackinnon, S; Robinson, SP; Russell, N; Schmitz, N; Taghipour, G | 1 |
| Aleĭnikova, OV; Pochetukhin, KV; Strongin, IuS | 1 |
| Albó, C; Arranz, R; Caballero, MD; Cabrera, R; Carreras, E; Conde, E; Fernández de Sevilla, A; Gandarillas, M; García Ruíz, JC; García-Conde, J; García-Laraña, J; Grande, C; Iriondo, A; Lahuerta, JJ; Marín, J; Moraleda, JM; Pérez-Equiza, C; Pérez-Simón, JA; Rifón, J; Rubio, V; San Miguel, JF; Sierra, J; Sureda, A; Varela, R; Vidal, MJ; Zuazu, J | 1 |
| García, J; Lahuerta, JJ; Lizasoain, M; Sanz, F | 1 |
| Jaffrey, I; Pashaei, S; Ryder, J; Sun, T | 1 |
| Grøttum, P; Kvalheim, G; Rusten, LS; Østby, I | 1 |
| Jantunen, E; Kuittinen, T; Nousiainen, T | 1 |
| Ball, ED; Bashey, A; Carrier, E; Chen, YA; Corringham, S; Holman, P; Wang, EH | 1 |
| Bosi, A; Bruzzi, P; Di Bartolomeo, P; Donelli, A; Filippi, M; Gualandi, F; Guerrasio, A; La Nasa, G; Mancardi, GL; Marmont, AM; Murialdo, A; Pagliai, F; Papineschi, F; Saccardi, R; Scappini, B; Solari, A | 1 |
| Boruczkowski, D; Choma, M; Chybicka, A; Drabko, K; Gorczyńska, E; Kałwak, K; Kowalczyk, JR; Pieczonka, A; Toporski, J; Turkiewicz, D; Wachowiak, J; Wójcik, B; Zaucha-Prazmo, A | 1 |
| Belford, D; Gates, P; Jablonskis, L; Januszewicz, H; Lillie, K; Prince, HM; Regester, G; Seymour, JF; West, R; Wolf, M | 1 |
| Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R | 1 |
| Bakshi, A; Bhagwat, R; Biswas, G; Khadwal, A; Narayanan, P; Parikh, P; Sastry, P | 1 |
| Antonenas, V; Bradstock, K; Collins, D; Crowther, H; Gottlieb, D; Kerridge, I; McGurgan, M | 1 |
| Bauchmüller, K; Engelhardt, M; Finke, J; Haas, PS; Ihorst, G; Kühnemund, A | 1 |
| Brambilla, G; Castagna, L; Magagnoli, M; Masci, G; Morenghi, E; Pedicini, V; Poretti, D; Santoro, A | 1 |
| Bahlis, N; Balogh, A; Brown, C; Jones, A; Morris, DG; Russell, JA; Savoie, L; Stewart, DA; Valentine, K | 1 |
| Gisselbrecht, C; Hagberg, H | 1 |
| Goh, YT; Hwang, WY; Koh, BC; Koh, LP; Linn, YC; Loh, SM; Ratnagopal, P; Tan, HC | 1 |
| Horvath, N; Keefe, D; Lees, J | 1 |
| Atkins, H; Bence-Bruckler, I; Bredeson, C; Huebsch, L; Leger, C; McDiarmid, S; Sabloff, M; Zhang, H | 1 |
| Aldouri, M; Devereux, S; Milojković, D; Mufti, GJ; Pagliuca, A | 1 |
| Cupelli, L; de la Rubia, J; Jarque, I; Jiménez, C; Lorenzo, I; Martín, G; Martínez, JA; Puig, N; Remigia, MJ; Sanz, GF; Sanz, J; Sanz, MA | 1 |
| Balzarotti, M; Bramanti, S; Castagna, L; Magagnoli, M; Mazza, R; Nozza, A; Russo, F; Santoro, A; Sarina, B; Siracusano, L; Timofeeva, I; Todisco, E | 1 |
| Dong, HQ; Ji, BX; Lu, CY; Lu, DP; Su, L; Wan, SG; Xu, J; Yu, YY | 1 |
| Bishton, MJ; Haynes, AP | 1 |
| Cağirgan, S; Ergene, U; Pehlivan, M; Tombuloğlu, M; Yilmaz, M | 1 |
| Bühlmann, M; Bükki, J; Ernst, S; Stanga, Z; Stucki, A | 1 |
| Huijgens, PC; Keijzer, A; van de Loosdrecht, AA | 1 |
| Avigdor, A; Ben-Bassat, I; Hardan, I; Nagler, A; Oksman, Y; Shem-Tov, N; Shimoni, A; Yerushalmi, R; Zwas, ST | 1 |
| Bu, Q; Cai, QQ; Gao, Y; Huang, HQ; Lin, XB; Peng, YL; Wang, BF | 1 |
| Blundell, E; Goldstone, AH; Linch, DC; Peggs, KS; Thomson, KJ | 1 |
| Abdelsalam, M; Akhtar, S; El Weshi, A; Hussaini, H; Janabi, I; Maghfoor, I; Rahal, M | 1 |
| Huh, J; Jang, G; Jo, JC; Kang, BW; Kim, JW; Kim, S; Koo, JE; Lee, SS; Suh, C; Sym, SJ | 1 |
| Bauchmüller, K; Engelhardt, M; Ihorst, G; Strobel, ES | 1 |
| Falk, P; Forman, SJ; Fung, HC; Krishnan, A; Molina, A; Nademanee, A; Palmer, JM; Raubitschek, AA; Rodriguez, R; Spielberger, RT; Yamauchi, D | 1 |
| Albo, C; Alonso, N; Arranz, R; Caballero, D; Conde, E; Fernández-Rañada, JM; Gandarillas, M; García Vela, JA; Garzón, S; Grande, C; Hernández, MT; Lahuerta, JJ; Mateos, MV; Rodríguez, J | 1 |
| Augustin, KM; Devine, SM; Dipersio, JF; Sempek, D; Vij, R; Wildes, TM; Zhang, QJ | 1 |
| Chondropoulos, S; Dervenoulas, J; Economopoulos, T; Giannopoulou, V; Girkas, K; Ioannidou, E; Kalli, T; Ladas, SD; Papageorgiou, E; Papaxoinis, G; Pappa, V; Triantafyllou, K; Tsirigotis, P | 1 |
| Erwin, W; Evens, AM; Gordon, LI; Inwards, DJ; Mehta, J; Micallef, I; Molina, A; Patton, D; Rademaker, AW; Singhal, S; Spies, S; Tallman, MS; Weitner, BB; White, CA; Williams, SF; Winter, JN; Wiseman, G; Zimmer, M | 1 |
| Martin, R; Schippling, S | 1 |
| Bahlis, N; Mansoor, A; Stewart, DA | 1 |
| Barosi, G; Fanti, S; Gianni, AM; Martelli, M; Petrini, M; Tura, S; Vitolo, U; Zinzani, PL | 1 |
| Aureli, V; Balduino, G; Caniglia, M; Cometa, AM; Isacchi, G; Landi, F; Miele, MJ; Pinto, RM; Rana, I; Scerpa, MC; Zinno, F | 1 |
| Asmar, L; Beveridge, R; Boehm, KA; Mandanas, R; McGaughey, D; Orloff, G; Rifkin, R; Spitzer, G; Zhan, F | 1 |
| Cornely, OA; Keulertz, C; Lövenich, H; Rüping, MJ; Söhngen, D; Vehreschild, JJ; Wieland, U | 1 |
| Buset, EM; Haile, SR; Honegger, H; Knuth, A; Mischo, A; Pestalozzi, BC; Petrausch, U; Renner, C; Samaras, P; Schanz, U; Siciliano, RD; Stahel, RA; Stenner-Liewen, F; Stussi, G | 1 |
| Bologna, S; Bosly, A; Bouabdallah, K; Brière, J; Coiffier, B; Decaudin, D; Delarue, R; Ghesquières, H; Gisselbrecht, C; Huynh, A; Le Gouill, S; Morschhauser, F; Mounier, N; Ribrag, V; Tilly, H | 1 |
| Bruno, A; Cantoni, F; Cupelli, L; Datturi, T; De Angelis, V; de Fabritiis, P; De Meis, I; Dentamaro, T; Niscola, P; Tendas, A | 1 |
| Briere, J; Bron, D; Cogliatti, S; Cuccuini, W; Gaulard, P; Gisselbrecht, C; Hirchaud, E; Houlgatte, R; Mounier, N; Rosenwald, A; Soulier, J; Sundstrom, C; Thieblemont, C; Voelker, HU; Ysebaert, L | 1 |
| Andersen, NS; Bentzen, H; Brown, P; Delabie, J; Ehinger, M; Elonen, E; Eriksson, M; Geisler, CH; Jerkeman, M; Karjalainen-Lindsberg, ML; Kimby, E; Kolstad, A; Kuittinen, O; Laurell, A; Lauritzsen, GF; Nilsson-Ehle, H; Nordström, M; Pedersen, LB; Ralfkiaer, E; Räty, R; Sundström, C | 1 |
| Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M | 1 |
| Bruno Ventre, M; Caligaris-Cappio, F; Cattaneo, C; Di Nicola, M; Donadoni, G; Ferreri, AJ; Foppoli, M; Fumagalli, L; Govi, S; Mappa, S; Re, A; Rossi, G; Spina, M; Tirelli, U | 1 |
| Armitage, JO; Bierman, PJ; Bociek, RG; Chan, WC; Enke, C; Hankins, J; Loberiza, FR; Vose, JM; Weisenburger, DD | 1 |
| Casper, J; Gebauer, W; Köhne, CH; Kraemer, D; Metzner, B; Müller, TH; Pott, C; Rosien, B; Schumann-Binarsch, S; Thole, R | 1 |
| Annereau, JP; Bailly, C; Bonnet, D; Brel, V; Créancier, L; Currie, E; Fournier, E; Gomes, B; Guilbaud, N; Guminski, Y; Kruczynski, A; Pillon, A; Vandenberghe, I | 1 |
| Bernal, T; Briones, J; Caballero, D; Canales, MA; García-Marco, JA; González-Barca, E; Grande, C; Hernández, M; Jarque, I; López, D; Moraleda, JM; Novelli, S; Palmero, F; Panizo, C; Tomás, JF; Torres, A | 1 |
| Boyce, TG; Burnette, BL; Jentoft, MA; Porrata, LF; Witzig, TE | 1 |
| Belada, D; Berková, A; Bolomská, I; Burešová, L; Campr, V; Klener, P; Kozák, T; Kubáčková, K; Matuška, M; Pirnos, J; Přibylová, J; Pytlík, R; Sýkorová, A; Trněný, M; Vášová, I | 1 |
| Berritta, D; Cupri, A; Fauci, AL; Leotta, S; Milone, G; Parisi, M; Spina, P; Tripepi, G | 1 |
| Abboud, CN; Cashen, AF; DiPersio, JF; Fiala, MA; Fletcher, T; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Wang, TF; Westervelt, P; Wu, N | 1 |
| Bordessoule, D; Bouabdallah, R; Bouteloup, M; Briere, J; Casasnovas, RO; Ciappuccini, R; Delmer, A; Fermé, C; Fruchart, C; Ghesquières, H; Gisselbrecht, C; Morschhauser, F; Tilly, H; Van Den Neste, E; Ysebaert, L | 1 |
| Forman, SJ; Hasenkamp, J; Krishnan, AY; Mei, M; Nademanee, A; Palmer, JM; Raubitschek, A; Shimoni, A; Simpson, J; Tsai, NC; Wondergem, MJ | 1 |
| Biron, P; Bouabdallah, R; Boumendil, A; Cahn, JY; Colombat, P; Cook, G; Cordonnier, C; Dreger, P; El-Najjar, I; Ferrant, A; Finel, H; Gribben, J; Haynes, AP; Luan, JJ; Mohty, M; Montoto, S; Pfreundschuh, M; Sureda, A; Thomson, K; Tilly, H; Vernant, JP | 1 |
| Cook, G; Fox, C; Johnson, P; Kirkland, K; McQuaker, G; Pagliuca, A; Pearce, R; Perry, J; Robinson, S; Russell, N; Truelove, E | 1 |
| Banz, Y; Berger, MD; Branger, G; Klaeser, B; Mueller, BU; Novak, U; Pabst, T; Taleghani, BM | 1 |
| Abela, EM; Anagnostopoulos, A; Apostolou, C; Baliakas, P; Batsis, I; Douka, V; Iskas, M; Kaloyannidis, P; Karypidis, K; Konstantinou, V; Kouvatseas, G; Mallouri, D; Marvaki, A; Sakellari, I; Smias, C; Sotiropoulos, D; Yannaki, E | 1 |
| Clark, SM; Clemmons, AB; DeRemer, DL; Garren, J; Kota, VK; Schaack, L | 1 |
| Brozova, J; Dobrovolny, J; Kozak, T; Novak, J; Novakova, L | 1 |
| Amorim, S; Bouabdallah, R; Boumendil, A; Choquet, S; de Rosa, G; Delmer, A; Dreger, P; Faber, E; Facchini, L; Falzetti, F; Ferrara, F; Finel, H; Finke, J; Kobbe, G; Nicolas-Virelizier, E; Salles, G; Sayer, H; Scime, R; Sellner, L; Sureda, A; Vallisa, D; Yakoub-Agha, I; Zuffa, E | 1 |
| Agresta, F; Ayton, R; Bennett, A; Bhattacharyya, P; Cooke, RE; Grigg, A; Lasica, M; Stern, C; Taylor, E | 1 |
| Chwieduk, A; Fidyk, W; Giebel, S; Głowala-Kosińska, M; Mitrus, I; Najda, J; Smagur, A | 1 |
| Chen, S; Lei, X; Tang, C; Xiong, YL; Xu, WJ; Zhao, KW; Zhou, Q | 1 |
| Chapuy, B; Feller, AC; Hasenclever, D; Hohloch, K; Loeffler, M; Pfreundschuh, M; Schmitz, N; Trümper, L; Wulf, G; Zeynalova, S; Ziepert, M | 1 |
| Christofides, A; Isidori, A; Visani, G | 1 |
| Ammari, S; Canova, C; Dercle, L; Deutsch, E; Levy, A; Marabelle, A; Mazeron, R; Michot, JM; Ribrag, V; Rose, S; Rubin, E; Soria, JC | 1 |
| Baran, A; Barr, PM; Becker, MW; Friedberg, JW; Liesveld, JL; Milner, LA; Phillips, GL; Reid, RM; Wedow, L | 1 |
| Bachanova, V; Brunstein, CG; Fair, C; Lazaryan, A; McClune, B; Rogosheske, J; Shanley, R | 1 |
| Bouabdallah, K; Cornillon, J; Damaj, G; Gastinne, T; Ghésquières, H; Gressin, R; Gyan, E; Ranchon, F; Salles, G; Vigouroux, S; Yakoub-Agha, I | 1 |
| Butcher, B; Chong, G; Cull, G; Fay, K; Filshie, R; Gandhi, MK; Gill, D; Grigg, A; Hahn, U; Hertzberg, M; Hicks, RJ; Ho, SJ; Hofman, MS; Johnston, A; Kannourakis, G; Lewis, ID; Milliken, S; Renwick, W; Seymour, JF; Taper, J; Trotman, J; Warburton, P; Watson, AM; Wirth, A | 1 |
| Billett, AL; Dahmoush, HM; Grant, FD; LaCasce, AS; Lehmann, LE; Margossian, SP; Ozuah, NW | 1 |
| Fan, B; Ge, J; Ge, L; Lu, H; Ma, J; Qian, J; Zhong, X | 1 |
| Bellò, M; Benevolo, G; Bisi, G; Boccomini, C; Botto, B; Castellino, A; Chiappella, A; Ciochetto, C; Freilone, R; Nicolosi, M; Orsucci, L; Passera, R; Pecoraro, C; Pregno, P; Vitolo, U | 1 |
| Dünweber, A; Fridthjof, KS; Friis, LS; Gørløv, JS; Kampmann, P; Kjeldsen, L; Moser, C; Møller, T; Nexø, C; Nørskov, KH; Welinder, PC | 1 |
| Andrick, B; Clemmons, AB; DeRemer, D; Gandhi, A; Orr, J; Sportes, C | 1 |
| Ali, H; Budde, E; Chen, R; Forman, SJ; Herrera, AF; Mei, M; Mokhtari, S; Nademanee, A; Nakamura, R; Popplewell, L; Salhotra, A; Sandhu, K; Stiller, T; Zain, J | 1 |
| Abounader, D; Andritsos, L; Benson, DM; Bolwell, B; Dean, R; Devine, SM; Efebera, YA; Elder, P; Hill, B; Hofmeister, CC; Jagadeesh, D; Jaglowski, S; Kalaycio, M; Majhail, NS; Penza, S; Pohlman, B; Rosko, A; Sharma, N; Singer, S; Sobecks, R; Vasu, S; William, BM; Zhao, Q | 2 |
| Arcani, R; Colle, J; Costello, RT; Fanciullino, R; Farnault, L; Ivanov, V; Jourde-Chiche, N; Mercier, C; Pourroy, B; Roche, P; Venton, G | 1 |
| Hagiwara, S; Ishiyama, M; Izuka, Y; Kazama, H; Osanai, S; Ryuzaki, M; Shinohara, A; Shiseki, M; Tanaka, J; Tanaka, N; Watanabe, A; Yoshinaga, K | 1 |
| Bashir, Q; Champlin, RE; Delgado, R; Hosing, C; Kebriaei, P; Lee, HC; Manasanch, EE; Mukherjee, A; Nieto, Y; Orlowski, RZ; Patel, KK; Patel, RD; Popat, U; Qazilbash, MH; Rondon, G; Saini, NY; Thomas, SK; Varma, A; Weber, DM | 1 |
| Barbon Gauro, J; Heng, MS; Thomas, J; Yaxley, A | 1 |
| Bañuelos-Ávila, AJ; Barrera-Chairez, E; Fernandez-Vargas, OE; Ron-Guerrero, CS; Ron-Magaña, AL | 1 |
| Bazarbachi, A; Bou Akl, I; El-Cheikh, J; Ghaoui, N; Karout, L; Khalil, PB; Massoud, R; Matar, M; Zahreddine, A | 1 |
| Charifa, A; Ko, CJ; Lee, A; Levy, L; McNiff, JM; Paulson, N; Perincheri, S | 1 |
| Cheng, B; Du, J; Fu, MH; Pan, YY; Tao, XF | 1 |
| Bosch, M; Danyluk, P; Dusyk, T; Elemary, M; Hahn, L; Lim, H; Sabry, W; Stakiw, J | 1 |
| Mizel, SB; Wilson, L | 1 |
14 review(s) available for podophyllotoxin and cytarabine
| Article | Year |
|---|---|
Antineoplastic drugs: clinical pharmacology and therapeutic use.
Topics: Alkaloids; Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Azacitidine; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Drug Interactions; Fluorouracil; Humans; Kinetics; Methotrexate; Podophyllotoxin | 1978 |
Drug level monitoring: cytostatics.
Topics: Alkylating Agents; Aminoacridines; Amsacrine; Anthraquinones; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Bleomycin; Busulfan; Chlorambucil; Chromatography, Gas; Chromatography, Liquid; Cisplatin; Cyclophosphamide; Cytarabine; Fluorouracil; Humans; Mass Spectrometry; Melphalan; Methotrexate; Mitomycins; Monitoring, Physiologic; Nitrosourea Compounds; Podophyllotoxin; Purines; Thiotepa; Vinca Alkaloids | 1985 |
[Prolonged intravenous infusion chemotherapy. General review of theoretical bases and results].
Topics: Antineoplastic Agents; Bleomycin; Cell Cycle; Cisplatin; Clinical Trials as Topic; Cytarabine; Doxorubicin; Fluorouracil; Humans; Infusions, Parenteral; Neoplasms; Podophyllotoxin; Time Factors; Vinca Alkaloids | 1985 |
Teniposide in the treatment of leukemia: a case study of conflicting priorities in the development of drugs for fatal diseases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Humans; Leukemia, Lymphoid; Podophyllotoxin; Teniposide | 1988 |
New cancer chemotherapeutic agents.
Topics: Aldehydes; Amides; Amines; Animals; Antineoplastic Agents; Asparaginase; Azacitidine; Azaguanine; Bleomycin; Carmustine; Chlorides; Cyclization; Cyclohexanes; Cytarabine; Cytidine; Doxorubicin; Glycosides; Humans; Hydroxyurea; Imidazoles; Leukemia, Lymphoid; Leukemia, Myeloid; Mice; Nitrosourea Compounds; Picolinic Acids; Platinum; Podophyllotoxin; Streptozocin; Thiosemicarbazones; Triazenes | 1972 |
Intensive therapy and autotransplantation in Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Digestive System Diseases; Etoposide; Heart Diseases; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lung Diseases; Melphalan; Multicenter Studies as Topic; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome; Whole-Body Irradiation | 1994 |
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
Topics: Adolescent; Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Movement; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Kidney Diseases; Leukapheresis; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Podophyllotoxin; Retrospective Studies; Thiotepa; Transplantation Conditioning | 1996 |
Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Encephalitis; Etoposide; Female; Humans; Immunoglobulins, Intravenous; Immunosuppression Therapy; Injections, Spinal; Interferon-alpha; Interleukin-12; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Melphalan; Memory Disorders; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 1999 |
Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Melphalan; Podophyllotoxin; Radiotherapy, Adjuvant; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2001 |
Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide.
Topics: Antineoplastic Agents; Child; Cyclophosphamide; Cytarabine; Humans; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction | 2001 |
Frequency, severity and risk factors for oral mucositis after BEAM conditioning and autologous peripheral blood stem cell transplantation: a single center analysis and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Prognosis; Risk Factors; Stomatitis; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2007 |
[Stem cell therapy in multiple sclerosis: a clinical update].
Topics: Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carmustine; Central Nervous System; Clinical Trials, Phase II as Topic; Controlled Clinical Trials as Topic; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Melphalan; Mitoxantrone; Multicenter Studies as Topic; Multiple Sclerosis; Podophyllotoxin; Risk Assessment; Survival Rate; Treatment Outcome | 2009 |
Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan; Podophyllotoxin; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2016 |
Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan; Podophyllotoxin | 2017 |
47 trial(s) available for podophyllotoxin and cytarabine
| Article | Year |
|---|---|
[Prolonged intravenous infusion chemotherapy. General review of theoretical bases and results].
Topics: Antineoplastic Agents; Bleomycin; Cell Cycle; Cisplatin; Clinical Trials as Topic; Cytarabine; Doxorubicin; Fluorouracil; Humans; Infusions, Parenteral; Neoplasms; Podophyllotoxin; Time Factors; Vinca Alkaloids | 1985 |
The epipodophyllotoxin teniposide in therapy for childhood acute lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphoid; Podophyllotoxin; Teniposide | 1988 |
The epipodophyllotoxin VP16-213 in combination chemotherapy for adults with acute nonlymphoblastic leukaemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Doxorubicin; Etoposide; Humans; Leukemia; Podophyllotoxin; Thioguanine | 1985 |
Evaluation of cyclocytidine in reinduction and maintenance therapy of children with acute nonlymphocytic leukemia previously treated with cytosine arabinoside: a report from Children's Cancer Study Group.
Topics: Adolescent; Adult; Ancitabine; Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Delayed-Action Preparations; Female; Humans; Infant; Injections, Intraperitoneal; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Lomustine; Male; Podophyllotoxin | 1984 |
In adult acute nonlymphoblastic leukaemia extended maintenance chemotherapy has no benefit.
Topics: Acute Disease; Adolescent; Adult; Cytarabine; Doxorubicin; Humans; Leukemia; Middle Aged; Podophyllotoxin; Prognosis | 1984 |
Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Confidence Intervals; Critical Care; Cytarabine; Erythrocyte Transfusion; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neutropenia; Platelet Transfusion; Podophyllotoxin; Preoperative Care; Prognosis; Recurrence; Salvage Therapy; Time Factors | 1995 |
Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Melphalan; Platelet Transfusion; Podophyllotoxin; Prospective Studies; Recombinant Proteins; Survival Analysis; Time Factors; Transplantation, Autologous | 1996 |
High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; L-Lactate Dehydrogenase; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Recurrence; Survival Rate; Transplantation, Autologous; Treatment Outcome | 1996 |
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
Topics: Adolescent; Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Movement; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Kidney Diseases; Leukapheresis; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Podophyllotoxin; Retrospective Studies; Thiotepa; Transplantation Conditioning | 1996 |
Impact of high-dose salvage therapy (BEAM) on overall survival in younger patients with advanced large-cell lymphomas entered into BNLI trials.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Podophyllotoxin; Prednisone; Salvage Therapy; Treatment Outcome; Vincristine | 1997 |
High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Risk Factors | 1997 |
CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy | 1998 |
Navoban (tropisetron, ICS 205-930) and dexamethasone combination in the prevention of vomiting for patients receiving preconditioning high-dose chemotherapy before marrow transplantation.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; Child; Cyclophosphamide; Cytarabine; Dexamethasone; Dizziness; Drug Therapy, Combination; Female; Headache; Heartburn; Humans; Indoles; Leukemia; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Transplantation Conditioning; Tropisetron; Vomiting; Whole-Body Irradiation | 1998 |
Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carmustine; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 1999 |
Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Prospective Studies; Survival Rate; Transplantation, Autologous | 2000 |
BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Survival Rate; Transplantation, Autologous | 2003 |
Trial of amifostine in autologous stem cell transplant.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Female; Graft Survival; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Radiation-Protective Agents; Stem Cell Transplantation; Transplantation, Homologous | 2006 |
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Recurrence; Remission Induction; Risk Factors; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Vincristine | 2006 |
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Remission Induction; Rituximab; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2006 |
Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Myeloablative Agonists; Podophyllotoxin; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2006 |
Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cancer Care Facilities; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Eruptions; Female; Fibroblast Growth Factor 7; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Middle Aged; Podophyllotoxin; Primary Prevention; Severity of Illness Index; South Australia; Stomatitis; Time Factors; Transplantation Conditioning; Treatment Outcome | 2006 |
Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neutropenia; Podophyllotoxin; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2006 |
Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Male; Melphalan; Middle Aged; Morbidity; Mortality; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous | 2006 |
Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Celiac Disease; Combined Modality Therapy; Cytarabine; Enteral Nutrition; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Immunosuppressive Agents; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome | 2007 |
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Radioimmunotherapy; Stem Cell Transplantation; Treatment Outcome; Yttrium Radioisotopes | 2008 |
Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Risk Assessment; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Vincristine | 2008 |
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Radioimmunotherapy; Radiotherapy Dosage; Salvage Therapy; Transplantation, Autologous | 2009 |
Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Neutropenia; Podophyllotoxin; Polyethylene Glycols; Recombinant Proteins; Transplantation, Autologous; Young Adult | 2010 |
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Melphalan; Middle Aged; Neoplasm Staging; Podophyllotoxin; Rituximab; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Genes, myc; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunotherapy; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Rituximab; Salvage Therapy; Transplantation, Autologous; Treatment Failure; Young Adult | 2012 |
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Recurrence; Rituximab; Survival Rate; Transplantation, Autologous | 2012 |
Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Melphalan; Middle Aged; Myeloablative Agonists; Podophyllotoxin; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2013 |
Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous | 2013 |
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Neoplasm Staging; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning | 2014 |
Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Prospective Studies; Risk Factors; Rituximab; Stem Cell Transplantation; Survival Rate | 2014 |
Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning | 2014 |
Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma.
Topics: Adult; Aged; Algorithms; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Podophyllotoxin; Rituximab; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning | 2016 |
Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Prospective Studies; Salvage Therapy; Transplantation, Autologous; Young Adult | 2016 |
BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Obesity; Podophyllotoxin; Prospective Studies; Transplantation Conditioning | 2017 |
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Positron-Emission Tomography; Prednisone; Retreatment; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2017 |
Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Child; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Melphalan; Podophyllotoxin; Positron-Emission Tomography; Preoperative Care; Retrospective Studies; Stem Cell Transplantation; Survival Rate | 2018 |
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Invasiveness; Podophyllotoxin; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Melphalan; Middle Aged; Morpholines; Nausea; Olanzapine; Ondansetron; Podophyllotoxin; Vomiting | 2018 |
Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin; Sirolimus; Survival Rate; Tacrolimus; Transplantation Conditioning | 2019 |
Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Lung; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Respiratory Function Tests; Retrospective Studies; Survival Rate; Transplantation Conditioning | 2020 |
136 other study(ies) available for podophyllotoxin and cytarabine
| Article | Year |
|---|---|
Structure-activity relationships of antineoplastic agents in multidrug resistance.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cricetinae; Dactinomycin; Drug Resistance; Leukemia L1210; Mice; Regression Analysis; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
[New drugs for the therapy of acute leukemia].
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Guanazole; Humans; Leukemia; Lomustine; Peptichemio; Podophyllotoxin; Razoxane; Zinostatin | 1975 |
Comparative study of early effects of epipodophyllotoxin derivatives and other cytostatic agents on mastocytoma cultures.
Topics: Antineoplastic Agents; Bleomycin; Cell Division; Cell Line; Colchicine; Cytarabine; DNA, Neoplasm; Etoposide; Mast-Cell Sarcoma; Mechlorethamine; Mercaptopurine; Methotrexate; Mitosis; Neoplasm Proteins; Neoplasms, Experimental; Podophyllotoxin; Razoxane; RNA, Neoplasm; Teniposide; Vincristine; X-Rays | 1977 |
Rapid remission induction in adult acute non-lymphoblastic leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Podophyllotoxin; Remission, Spontaneous; Sepsis; Time Factors | 1978 |
Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia.
Topics: Animals; Antineoplastic Agents; Carmustine; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Drug Therapy, Combination; Etoposide; Female; Fluorouracil; Leukemia L1210; Male; Mercaptopurine; Methotrexate; Mice; Mice, Inbred DBA; Podophyllotoxin; Vincristine | 1976 |
[The treatment of acute myelocytic leukemia during the first recurrence by means of a new cytostatic combination].
Topics: Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Leukemia, Myeloid, Acute; Podophyllotoxin; Thioguanine; Vincristine | 1976 |
Letter: Epipodophyllotoxin VP 16213 in acute non-lymphoblastic leukaemia.
Topics: Cytarabine; Doxorubicin; Drug Therapy, Combination; Humans; Leukemia; Podophyllotoxin; Thiophenes | 1975 |
Letter: Treatment of acute leukaemia.
Topics: Acute Disease; Cytarabine; Doxorubicin; Drug Therapy, Combination; Humans; Leukemia; Methotrexate; Podophyllotoxin | 1975 |
Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213.
Topics: Animals; Cytarabine; Drug Therapy, Combination; Etoposide; Female; Leukemia L1210; Leukemia, Experimental; Mice; Podophyllotoxin; Pyrans; Teniposide | 1975 |
Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion, Autologous; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Salvage Therapy; Whole-Body Irradiation | 1992 |
Effects of the lipophilic anticancer drug teniposide (VM-26) on membrane transport.
Topics: Amino Acids; Animals; Biological Transport; Carcinoma, Ehrlich Tumor; Carrier Proteins; Cell Membrane; Cell Membrane Permeability; Cytarabine; Etoposide; Humans; Membrane Lipids; Membranes, Artificial; Nucleosides; Podophyllotoxin; Teniposide; Tumor Cells, Cultured | 1990 |
[Kinetics of etoposide cytotoxicity against mouse P388 leukemia].
Topics: Animals; Bleomycin; Cell Cycle; Cell Survival; Cisplatin; Colony-Forming Units Assay; Cytarabine; Doxorubicin; Etoposide; Fluorouracil; Leukemia P388; Leukemia, Experimental; Melphalan; Mice; Peplomycin; Podophyllotoxin; Tumor Stem Cell Assay; Vinblastine | 1985 |
Recombinant human granulocyte-macrophage colony-stimulating factor plus the beam regimen instead of autologous bone marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colony-Stimulating Factors; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Recombinant Proteins | 1989 |
VP-16 in combinations for first-line treatment of malignant germ-cell tumors and gestational choriocarcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Choriocarcinoma; Chorionic Gonadotropin; Cyclophosphamide; Cytarabine; Dactinomycin; Etoposide; Female; Humans; Male; Methotrexate; Neoplasms, Germ Cell and Embryonal; Podophyllotoxin; Pregnancy; Uterine Neoplasms; Vincristine | 1985 |
Cross-resistance of novobiocin-resistant BHK cell line to topoisomerase II inhibitors.
Topics: Amsacrine; Animals; Cell Line; Colchicine; Cytarabine; DNA Damage; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Novobiocin; Podophyllotoxin; Vinblastine | 1988 |
Treatment of lymphohistiocytic erythrophagocytosis with VP-16 and aziridinylbenzoquinone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Child, Preschool; Cyclohexenes; Cytarabine; Female; Histiocytic Sarcoma; Humans; Hydrocortisone; Infant, Newborn; Male; Methotrexate; Podophyllotoxin; Prednisone; Remission Induction; Thiotepa; Time Factors | 1987 |
[Cytosine arabinoside and VM-26 in induction treatment, failures and recurrences of childhood acute lymphoblastic leukemias].
Topics: Child; Child, Preschool; Cytarabine; Drug Combinations; Female; Humans; Male; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Risk Factors; Teniposide | 1988 |
Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Ifosfamide; Lymphoma; Melphalan; Methotrexate; Middle Aged; Mitoguazone; Podophyllotoxin | 1988 |
[VAMA salvage regimen (VP-16, ARA-C, MTX and L-asparaginase) in relapsed or resistant non-Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Drug Resistance; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Podophyllotoxin; Remission Induction | 1988 |
Teniposide (VM-26) and ara-C in the treatment of adult acute lymphoblastic leukemia.
Topics: Adult; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Lymphoid; Male; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Teniposide; Vincristine | 1987 |
Teniposide (VM-26) and cytosine arabinoside as consolidation therapy in adult high-risk patients with acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Lymphoid; Middle Aged; Podophyllotoxin; Prognosis; Teniposide | 1987 |
Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Female; Hodgkin Disease; Humans; Lymphoma; Male; Melphalan; Methotrexate; Middle Aged; Podophyllotoxin | 1986 |
High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Female; Humans; Leukemia; Liver; Male; Middle Aged; Podophyllotoxin; Recurrence; Time Factors | 1987 |
A novel treatment of childhood lymphoblastic non-Hodgkin's lymphoma: early and intermittent use of teniposide plus cytarabine.
Topics: Adolescent; Child; Child, Preschool; Cytarabine; Drug Therapy, Combination; Female; Humans; Infant; Injections, Spinal; Lymphoma; Male; Methotrexate; Podophyllotoxin; Prognosis; Teniposide; Thymus Gland | 1985 |
[Induction of remission by sequential treatment with cytosine arabinoside (araC/high dose) and L-asparaginase].
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia; Leukemia, Lymphoid; Male; Middle Aged; Podophyllotoxin | 1985 |
[Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia].
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia; Lymphoma; Male; Myeloproliferative Disorders; Podophyllotoxin | 1986 |
Inhibition of 1-beta-D-arabinofuranosylcytosine transport and net accumulation by teniposide and etoposide in Ehrlich ascites cells and human leukemic blasts.
Topics: Animals; Binding Sites; Biological Transport; Carcinoma, Ehrlich Tumor; Cells, Cultured; Cytarabine; Etoposide; Humans; Leukemia; Male; Mice; Mice, Inbred Strains; Podophyllotoxin; Teniposide; Thioinosine; Tritium | 1985 |
Malignant histiocytosis. Response to VP-16-213 and cytosine arabinoside.
Topics: Aged; Cytarabine; Etoposide; Female; Humans; Lymph Nodes; Lymphatic Diseases; Podophyllotoxin | 1984 |
[VP 16-213 in the treatment of acute leukemia in childhood].
Topics: Acute Disease; Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cytarabine; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia; Leukemia, Lymphoid; Male; Podophyllotoxin | 1983 |
Bone marrow fibre content in acute myeloid leukaemia before and after treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Collagen; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Podophyllotoxin; Primary Myelofibrosis; Reticulin; Thioguanine | 1984 |
[VM-26 and cytosine arabinoside in the treatment of acute refractory lymphoblastic leukemia in adults].
Topics: Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Drug Evaluation; Female; Humans; Leukemia, Lymphoid; Male; Podophyllotoxin; Teniposide | 1984 |
[Treatment of acute refractory lymphoblastic leukemia in the adult with VM-26 and ARA-C].
Topics: Adolescent; Adult; Child; Cytarabine; Female; Humans; Leukemia, Lymphoid; Male; Middle Aged; Podophyllotoxin; Teniposide | 1984 |
The treatment of childhood leukaemia in Hungary. On behalf of the Hungarian Working Party on Childhood Leukaemia.
Topics: Actuarial Analysis; Adolescent; Asparaginase; Central Nervous System; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Humans; Hungary; Infant; Leukemia, Lymphoid; Long-Term Care; Male; Methotrexate; Podophyllotoxin; Risk | 1982 |
VM-26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia.
Topics: Adolescent; Antineoplastic Agents; Bone Marrow Diseases; Child; Child, Preschool; Cytarabine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Infant; Leukemia, Lymphoid; Male; Mercaptopurine; Methotrexate; Podophyllotoxin; Remission, Spontaneous; Teniposide | 1980 |
The treatment of acute lymphoblastic leukaemia.
Topics: Adult; Bone Marrow Transplantation; Child; Cytarabine; Humans; Leukemia, Lymphoid; Male; Mercaptopurine; Methotrexate; Podophyllotoxin; Prognosis; Transplantation, Homologous | 1980 |
The University of Cape Town leukaemia centre: the first 5 years.
Topics: Academic Medical Centers; Acute Disease; Bone Marrow Transplantation; Cytarabine; Doxorubicin; Drug Therapy, Combination; Humans; Leukapheresis; Leukemia; Podophyllotoxin; South Africa; Transplantation, Homologous | 1980 |
VM26 therapy in children with drug-refractory lymphocytic leukemia.
Topics: Child; Cytarabine; Drug Evaluation; Drug Resistance; Drug Therapy, Combination; Humans; Leukemia, Lymphoid; Podophyllotoxin; Prednisone; Teniposide; Vincristine | 1982 |
Combined VM-26 and cytosine arabinoside in treatment of refractory childhood lymphocytic leukemia.
Topics: Adolescent; Adult; Bone Marrow; Child; Child, Preschool; Cytarabine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hypotension; Leukemia, Lymphoid; Male; Podophyllotoxin; Recurrence; Remission, Spontaneous; Teniposide | 1980 |
Sedimentation of DNA from L1210 cells after treatment with 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) or 1-beta-D-arabinofuranosylcytosine or both drugs.
Topics: Animals; Antibiotics, Antineoplastic; Centrifugation, Density Gradient; Cytarabine; Dose-Response Relationship, Drug; Drug Interactions; Leukemia L1210; Mice; Podophyllotoxin; Teniposide; Time Factors | 1980 |
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Bone Marrow Cells; Carboplatin; Carmustine; Cell Adhesion Molecules; Cell Movement; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Epirubicin; Etoposide; Female; Fluorouracil; Gene Expression; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; L-Selectin; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Neutrophils; Platelet Count; Podophyllotoxin; Receptors, Very Late Antigen; Thiotepa | 1995 |
Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Graft Rejection; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Life Tables; Lymphoma, Follicular; Melphalan; Middle Aged; Pancytopenia; Podophyllotoxin; Prednisone; Prognosis; Teniposide; Treatment Outcome; Vincristine; Whole-Body Irradiation | 1995 |
Functional hyperactivity of monocytes after bone marrow transplantation: possible relevance for the development of post-transplant complications or relapse.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopterins; Bone Marrow Transplantation; Busulfan; Carmustine; Cells, Cultured; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Susceptibility; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Leukemia; Lymphoma; Male; Melphalan; Middle Aged; Monocytes; Neopterin; Podophyllotoxin; Respiratory Burst; Superoxides; Tumor Necrosis Factor-alpha; Whole-Body Irradiation | 1995 |
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukapheresis; Lymphocyte Count; Lymphocyte Subsets; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Mesna; Middle Aged; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Time Factors; Treatment Outcome; Vincristine | 1995 |
[Differentiation therapy for myelodysplastic syndrome].
Topics: Adult; Aged; Aged, 80 and over; Cell Differentiation; Cytarabine; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Podophyllotoxin | 1993 |
Induction of ovarian function by using short-term human menopausal gonadotrophin in patients with ovarian failure following cytotoxic chemotherapy for haematological malignancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Female; Follicle Stimulating Hormone; Hodgkin Disease; Humans; Leukemia, Myelomonocytic, Acute; Luteinizing Hormone; Melphalan; Menotropins; Ovulation Induction; Podophyllotoxin; Prednisone; Pregnancy; Pregnancy, Multiple; Primary Ovarian Insufficiency; Remission Induction; Teniposide; Thioguanine; Vincristine | 1993 |
Pregnancy after autologous bone marrow transplantation for malignant lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Infant, Newborn; Lymphoma, Large B-Cell, Diffuse; Mechlorethamine; Melphalan; Podophyllotoxin; Prednisone; Pregnancy; Pregnancy Outcome; Procarbazine; Remission Induction; Salvage Therapy; Vincristine | 1994 |
Successful mobilisation of blood stem cells following previous autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Etoposide; Hematopoietic Stem Cells; Humans; Ifosfamide; Leukapheresis; Lymphoma, Follicular; Male; Melphalan; Methotrexate; Podophyllotoxin; Prednisolone; Prednisone; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 1996 |
G-CSF (filgrastim)-stimulated whole blood kept unprocessed at 4 degrees C does support a BEAM-like regimen in bad-risk lymphoma.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cold Temperature; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin | 1996 |
[Hemopoietic stem cell transplantation in lymphogranulomatosis].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carmustine; Child; Cytarabine; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Length of Stay; Male; Melphalan; Podophyllotoxin; Recurrence; Treatment Outcome | 1997 |
BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cytarabine; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Treatment Outcome | 1997 |
[Autologous transplant with BEAM protocol in lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Remission Induction; Transplantation Conditioning; Transplantation, Autologous | 1997 |
Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Bone Marrow; Carmustine; Combined Modality Therapy; Cryopreservation; Cyclophosphamide; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Neoplasms; Podophyllotoxin; Treatment Failure | 1998 |
Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Female; Heart; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lung; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neutropenia; Neutrophils; Podophyllotoxin; Respiratory Function Tests; Retrospective Studies; Ventricular Function, Left | 1998 |
[Intensive treatment of T-cell-rich B lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lymphoma, B-Cell; Male; Melphalan; Podophyllotoxin; Prednisone; Remission Induction; T-Lymphocyte Subsets; Vincristine | 1998 |
Clonal myelodysplastic cells present in apheresis product before transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Aberrations; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 7; Cyclophosphamide; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lymphoma, B-Cell; Lymphoma, Follicular; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies | 1998 |
Haemopoietic cell transplantation activity and results: a single institution experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Hungary; Leukemia; Melphalan; Podophyllotoxin; Recurrence; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1998 |
Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.
Topics: Adult; Ambulatory Care; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Neutropenia; Podophyllotoxin; Retrospective Studies | 1999 |
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 1999 |
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Chlorambucil; Cohort Studies; Combined Modality Therapy; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Incidence; Infant; Leukemia, Myeloid; Life Tables; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Prednisolone; Prednisone; Procarbazine; Retrospective Studies; Risk; Salvage Therapy; Vinblastine; Vincristine | 1999 |
Stem cell transplantations in patients with malignant lymphoma: costs in a Dutch university hospital in the period 1984-1995.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Hematopoietic Stem Cell Transplantation; Hospital Costs; Hospital Units; Hospitalization; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Melphalan; Netherlands; Parenteral Nutrition; Patient Isolation; Podophyllotoxin; Prednisone; Retrospective Studies; Transplantation, Autologous; Vincristine | 1999 |
Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Child; Child, Preschool; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Humans; Infant; Injections, Spinal; Leukemia-Lymphoma, Adult T-Cell; Leukemic Infiltration; Male; Methotrexate; Podophyllotoxin; Prognosis; Remission Induction; Risk; Teniposide; Treatment Outcome | 2000 |
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclosporine; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoproliferative Disorders; Male; Melphalan; Methotrexate; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Transplantation, Homologous | 2000 |
Automated immature reticulocyte counts are early markers of engraftment following autologous PBSC transplantation in patients with lymphoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Automation; Biomarkers; Carmustine; Cytarabine; Female; Flow Cytometry; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Neutrophils; Podophyllotoxin; Predictive Value of Tests; Reticulocyte Count; Reticulocytes; Time Factors; Transplantation, Autologous | 2000 |
Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Carmustine; Cell Lineage; Combined Modality Therapy; Cytarabine; Disease Susceptibility; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infections; Lymphocyte Count; Lymphocyte Subsets; Lymphopenia; Male; Melphalan; Middle Aged; Podophyllotoxin; Sweden; Transplantation Conditioning; Transplantation, Autologous | 2000 |
Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma.
Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Remodeling; Bone Resorption; Carmustine; Clodronic Acid; Combined Modality Therapy; Cytarabine; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoenzymes; Male; Melphalan; Middle Aged; Multiple Myeloma; Osteoclasts; Peptide Fragments; Podophyllotoxin; Procollagen; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2000 |
Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Topics: Adolescent; Adult; Age Factors; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infections; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Survival Rate; Time Factors; Transplantation Conditioning | 2000 |
Two-step immunoablative treatment with autologous peripheral blood CD34(+) cell transplantation in an 8-year-old boy with autoimmune haemolytic anaemia.
Topics: Anemia, Hemolytic, Autoimmune; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cyclophosphamide; Cytarabine; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Melphalan; Methylprednisolone; Plasmapheresis; Podophyllotoxin; Prednisolone; Splenectomy; Stem Cells; Transplantation, Autologous; Treatment Outcome | 2000 |
[High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cytarabine; Dacarbazine; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Procarbazine; Recurrence; Retrospective Studies; Survival Rate; Time Factors; Vinblastine; Vincristine | 2000 |
Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Blood Sedimentation; Carmustine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Recurrence; Salvage Therapy; Sex Factors; Survival Analysis; Transplantation, Autologous | 2001 |
Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Topics: Adjuvants, Immunologic; Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cells, Cultured; Cytarabine; Cytotoxicity Tests, Immunologic; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Interferon-alpha; Interleukin-2; K562 Cells; Killer Cells, Natural; Lymphocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Time Factors; Transplantation Conditioning; Transplantation, Autologous | 2001 |
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Prognosis; Radiopharmaceuticals; Survival Analysis; Survival Rate; Tomography, Emission-Computed; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation | 2002 |
Unusual implantation site of a port-a-cath system via the right femoral vein.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Catheterization, Central Venous; Catheters, Indwelling; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Mediastinal Neoplasms; Melphalan; Podophyllotoxin; Radiography; Thrombosis; Transplantation, Autologous | 2002 |
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Europe; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Proportional Hazards Models; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
[High-dose chemotherapy with autologous bone marrow transplantation in children with high-risk malignant neoformations].
Topics: Adolescent; Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carboplatin; Carmustine; Child; Child, Preschool; Cytarabine; Dacarbazine; Data Interpretation, Statistical; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Hodgkin Disease; Humans; Infant; Lymphoma, Non-Hodgkin; Male; Melphalan; Podophyllotoxin; Rhabdomyosarcoma; Sarcoma, Ewing; Sex Factors; Statistics, Nonparametric; Time Factors; Transplantation, Autologous; Vinblastine | 2002 |
High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Cytokines; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; L-Lactate Dehydrogenase; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2003 |
[Bacteremia due to Capnocytophaga spp.: two cases].
Topics: 4-Quinolones; Aged; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Capnocytophaga; Carmustine; Combined Modality Therapy; Cytarabine; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacterial Infections; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Transplantation Conditioning | 2003 |
A hybrid form of myeloid/NK-cell acute leukemia and myeloid/NK-cell precursor acute leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; CD2 Antigens; Cytarabine; Flow Cytometry; Humans; Immunophenotyping; Killer Cells, Natural; Leukemia, Lymphoid; Male; Melphalan; Podophyllotoxin | 2003 |
A mathematical model for reconstitution of granulopoiesis after high dose chemotherapy with autologous stem cell transplantation.
Topics: Adult; Algorithms; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Differentiation; Cell Division; Computer Simulation; Cytarabine; Dose-Response Relationship, Drug; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Kinetics; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Models, Biological; Myelopoiesis; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Transplantation, Autologous | 2003 |
High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Male; Melphalan; Middle Aged; Multiple Sclerosis; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Quality of Life; Radiography; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2005 |
[Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Melphalan; Podophyllotoxin; Poland; Retrospective Studies; Survival Analysis; Time Factors; Transplantation, Autologous; Treatment Outcome | 2004 |
A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy.
Topics: Adult; Aged; Animals; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cattle; Complex Mixtures; Cytarabine; Dose-Response Relationship, Drug; Female; Growth Substances; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Milk; Mouth Mucosa; Mouthwashes; Podophyllotoxin; Stomatitis | 2005 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Epirubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Odds Ratio; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy; Time Factors; Transplantation Conditioning; Treatment Outcome | 2005 |
Successful autologous peripheral blood stem cell harvest and transplant in a patient with cold agglutinins.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryoglobulins; Cytarabine; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Transplantation, Autologous | 2006 |
Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Remission Induction; Retrospective Studies; Transplantation, Autologous | 2006 |
Prophylaxis of central venous catheter-related thrombosis with minidose warfarin in patients treated with high-dose chemotherapy and peripheral-blood stem-cell transplantation: retrospective analysis of 228 cancer patients.
Topics: Administration, Oral; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Catheterization, Central Venous; Cytarabine; Female; Hemorrhage; Humans; Male; Melphalan; Neoplasms; Peripheral Blood Stem Cell Transplantation; Platelet Count; Podophyllotoxin; Retrospective Studies; Risk Factors; Transplantation, Homologous; Venous Thrombosis; Warfarin | 2006 |
Prolonged remission in a case of Richter's transformation of B-cell chronic lymphocytic leukaemia following adoptive immunotherapy.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Transformation, Neoplastic; Cyclophosphamide; Cytarabine; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Transfusion; Melphalan; Podophyllotoxin; Prednisone; Remission Induction; Rituximab; Time Factors; Vincristine | 2006 |
Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Hodgkin Disease; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Prospective Studies; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Autologous; Vinblastine; Vinorelbine | 2007 |
Autologous peripheral blood stem cell transplantation for severe multiple sclerosis.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Diarrhea; Disease-Free Survival; Female; Hematopoietic Stem Cell Mobilization; Humans; Liver Diseases; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Mucositis; Multiple Sclerosis; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2006 |
Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Component Removal; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Humans; Kinetics; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Autologous | 2007 |
[What is your diagnosis? Neutropenic colitis (neutropenic typhlitis)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cecum; Colon; Combined Modality Therapy; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Tomography, X-Ray Computed; Typhlitis | 2007 |
Palifermin and palmar-plantar erythrodysesthesia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Hypersensitivity; Female; Fibroblast Growth Factor 7; Foot Dermatoses; Hand Dermatoses; Humans; Lymphoma, B-Cell; Melphalan; Middle Aged; Mitogens; Podophyllotoxin | 2007 |
[Transdermal fentanyl in treating severe painful mucositis caused by autologous hematopoietic stem cell transplantation].
Topics: Administration, Cutaneous; Adolescent; Adult; Analgesics, Opioid; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Fentanyl; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mucositis; Pain; Pain Measurement; Podophyllotoxin; Quality of Life; Transplantation, Homologous; Young Adult | 2007 |
A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Podophyllotoxin; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2007 |
Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cohort Studies; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Multivariate Analysis; Neoplasm Staging; Podophyllotoxin; Prognosis; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Treatment Outcome | 2007 |
BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies; Survival Rate; Transplantation, Autologous | 2008 |
Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft Survival; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies; Severity of Illness Index; Stem Cell Transplantation; Transplantation, Autologous | 2008 |
Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capsule Endoscopy; Carmustine; Cytarabine; Female; Fibroblast Growth Factor 7; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Intestinal Diseases; Male; Melphalan; Middle Aged; Mucositis; Podophyllotoxin; Transplantation, Autologous | 2008 |
pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Neoplasm Proteins; Phosphorylation; Phosphotyrosine; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Protein Processing, Post-Translational; STAT3 Transcription Factor; Transplantation, Autologous; Tumor Suppressor Protein p53; Vincristine | 2009 |
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Hematology; Humans; Italy; Lymphoma, Non-Hodgkin; Melphalan; Podophyllotoxin; Practice Guidelines as Topic; Recurrence; Societies, Medical; Time Factors | 2010 |
Immunomagnetic selection of CD34(+) cells carried out in cryopreserved cell concentrates from a paediatric patient affected with non-Hodgkin lymphoma.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Preservation; Carmustine; Cell Count; Child, Preschool; Combined Modality Therapy; Cryopreservation; Cyclophosphamide; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunomagnetic Separation; Leukapheresis; Lymphoma, Large-Cell, Anaplastic; Melphalan; Podophyllotoxin; Recurrence; Transplantation, Autologous | 2010 |
Association of HSV reactivation and pro-inflammatory cytokine levels with the severity of stomatitis after BEAM chemotherapy and autologous SCT.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Cytokines; Female; Herpesvirus 1, Human; Herpesvirus 2, Human; Hodgkin Disease; Humans; Inflammation; Interleukin-1; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Saliva; Severity of Illness Index; Statistics as Topic; Stem Cell Transplantation; Stomatitis; Transplantation, Autologous; Tumor Necrosis Factor-alpha; Young Adult | 2011 |
Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neutropenia; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Polyethylene Glycols; Recombinant Proteins; Severity of Illness Index; Thrombocytopenia; Time Factors; Transplantation, Autologous; Treatment Outcome; Young Adult | 2010 |
Single-dose pegylated-filgrastim versus daily filgrastim after high-dose chemotherapy and autologous stem cell transplantation for lymphoid malignancies: delayed platelets recovery?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Carmustine; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Platelet Count; Podophyllotoxin; Polyethylene Glycols; Recombinant Proteins; Recovery of Function; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2012 |
Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carmustine; Cytarabine; Female; HIV Seropositivity; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Stem Cell Transplantation; Transplantation, Autologous | 2012 |
Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Podophyllotoxin; Remission Induction; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Treatment Outcome | 2013 |
F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cytarabine; Deoxycytidine; Doxorubicin; Fetal Blood; Flow Cytometry; Gemcitabine; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Interleukin Receptor Common gamma Subunit; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Podophyllotoxin; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Vorinostat; Xenograft Model Antitumor Assays | 2013 |
Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive management.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain; Carmustine; Central Nervous System Neoplasms; Cesarean Section; Cytarabine; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Melphalan; Methotrexate; Podophyllotoxin; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Rituximab; Transplantation, Autologous; Treatment Outcome | 2014 |
Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Induction Chemotherapy; Lymphoma, B-Cell; Male; Melphalan; Methylprednisolone; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Podophyllotoxin; Prednisone; Prognosis; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2015 |
Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Female; Fibrinogen; Fibroblast Growth Factor 7; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infection Control; Male; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies; Thiotepa; Transplantation Conditioning; Young Adult | 2014 |
The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Remission Induction; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; Whole-Body Irradiation; Young Adult | 2014 |
Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
Topics: Adolescent; Adult; Alemtuzumab; Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bone Marrow Transplantation; Carmustine; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Registries; Societies, Medical; Survival Rate; Transplantation Conditioning; United Kingdom | 2015 |
Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgk
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Matched-Pair Analysis; Melphalan; Middle Aged; Neoplasm Staging; Podophyllotoxin; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2015 |
Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant.
Topics: Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Morpholines; Nausea; Podophyllotoxin; Prospective Studies; Retrospective Studies; Transplantation Conditioning; Vomiting | 2016 |
Recovery of mucosal-associated invariant T cells after myeloablative chemotherapy and autologous peripheral blood stem cell transplantation.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carmustine; Cytarabine; Female; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Mucosal-Associated Invariant T Cells; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous | 2016 |
Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin; Registries; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thiotepa | 2016 |
Fertility in premenopausal women post autologous stem cell transplant with BEAM conditioning.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Fertility; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Podophyllotoxin; Premenopause; Retrospective Studies; Transplantation Conditioning; Young Adult | 2016 |
Thymic Activity and T Cell Repertoire Recovery after Autologous Hematopoietic Stem Cell Transplantation Preceded by Myeloablative Radiotherapy or Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Thymus Gland; Transplantation Conditioning; Whole-Body Irradiation | 2016 |
Clinical assessment of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for endometrial cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Californium; Carmustine; Combined Modality Therapy; Cytarabine; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Melphalan; Middle Aged; Podophyllotoxin; Survival Rate; Treatment Outcome | 2016 |
Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Hodgkin Disease; Humans; Male; Melphalan; Neoplasm Metastasis; Podophyllotoxin; Programmed Cell Death 1 Receptor; Remission Induction; Salvage Therapy | 2016 |
Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cost-Benefit Analysis; Cytarabine; Female; Follow-Up Studies; Health Care Costs; Hematopoietic Stem Cell Transplantation; Humans; Infections; Kaplan-Meier Estimate; Lymphoma; Male; Melphalan; Middle Aged; Outpatients; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2016 |
Safety and feasibility of a low frame rate protocol for percutaneous coronary intervention to chronic total occlusions: preliminary experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Coronary Angiography; Coronary Occlusion; Cytarabine; Daunorubicin; Feasibility Studies; Humans; Percutaneous Coronary Intervention; Podophyllotoxin; Registries; Thioguanine; Treatment Outcome | 2018 |
Systematic patient involvement for homebased outpatient administration of complex chemotherapy in acute leukemia and lymphoma.
Topics: Acute Disease; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Humans; Infusion Pumps; Leukemia; Lymphoma; Male; Melphalan; Middle Aged; Outpatients; Podophyllotoxin | 2018 |
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Young Adult | 2019 |
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Young Adult | 2019 |
Severe renal insufficiency is not an absolute pitfall to autologous stem cell transplantation with BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning regimen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Humans; Lymphoma, B-Cell; Male; Melphalan; Podophyllotoxin; Renal Insufficiency; Severity of Illness Index; Stem Cell Transplantation; Transplantation Conditioning | 2019 |
Herpes zoster after autologous haematopoietic stem cell transplantation without antiviral prophylaxis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Herpes Zoster; Humans; Melphalan; Middle Aged; Podophyllotoxin | 2019 |
Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Survival Rate; Transplantation, Autologous; Waldenstrom Macroglobulinemia | 2019 |
Does a neutropenic diet reduce adverse outcomes in patients undergoing chemotherapy?
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacterial Infections; Carmustine; Chemotherapy-Induced Febrile Neutropenia; Cytarabine; Diet Therapy; Enterocolitis, Neutropenic; Female; Hematologic Neoplasms; Humans; Idarubicin; Male; Melphalan; Middle Aged; Neutropenia; Podophyllotoxin; Retrospective Studies; South Australia | 2020 |
BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Podophyllotoxin; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2019 |
Intravascular Large B-Cell Lymphoma: Clinical and Histopathologic Findings.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Vessels; Carmustine; Cyclophosphamide; Cytarabine; Delayed Diagnosis; Diagnosis, Differential; Doxorubicin; Early Detection of Cancer; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Podophyllotoxin; Prednisone; Rituximab; Skin; Skin Neoplasms; Treatment Outcome; Vincristine | 2020 |
Safety and efficacy of a low frame rate protocol for percutaneous coronary intervention for chronic total occlusions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Coronary Angiography; Coronary Occlusion; Cytarabine; Daunorubicin; Humans; Percutaneous Coronary Intervention; Podophyllotoxin; Thioguanine; Treatment Outcome | 2021 |
BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Neoplasms; Outcome Assessment, Health Care; Podophyllotoxin; Transplantation Conditioning | 2021 |
Nucleoside transport in mammalian cells. Inhibition by colchicine.
Topics: Adenosine; Alkaloids; Aminoisobutyric Acids; Animals; Carbon Isotopes; Carcinoma; Cell Line; Cells, Cultured; Colchicine; Cricetinae; Cytarabine; Dactinomycin; Fetus; Fibroblasts; Guanosine; HeLa Cells; Hexoses; Humans; Lung; Mouth Neoplasms; Nucleic Acids; Nucleosides; Phosphorus Isotopes; Plants, Medicinal; Plants, Toxic; Podophyllum; Skin; Thymidine; Tritium; Uridine | 1972 |